ARS Pharmaceuticals, Inc. SPRY
What this company does
Written from the business description in ARS Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 9 March 2026. Every sentence was checked against that document before publication.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 92 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.2 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.2 | 0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.2 | 0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.74 | 0.08 | −0.57 | −0.87 | −0.70 | −11.33 |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | −92.3 | 3.3 | −21.6 | −28.7 | · | · |
| Shares out B | 0.10 | 0.10 | 0.10 | 0.09 | 0.03 | 0.03 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 6 of 19 fiscal years. 70 checks could not be computed.